Abstract 172P
Background
Despite the high incidence rate and poor prognosis of lung cancers with liver metastases, effective treatment for this population remains an unmet need. Anlotinib (a novel anti-angiogenesis agent) could reprogramme the tumor microenvironment and normalize tumor vessel, improving the liver immunosuppressive microenvironment and liver metastases. However, the real-world evidence with anlotinib for this population is limited. Here we report the real-world data of efficacy and safety of anlotinib for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with liver metastases in China.
Methods
We reviewed the real-world records of patients treated with anlotinib in any line of treatment for solid tumors with liver metastases through 5 large hospitals in China from Jan, 2016 to Feb, 2023. Patients with hepatocellular carcinoma and those who had received locoregional therapy during anlotinib treatment were excluded. In this abstract, we present data from patients with NSCLC and SCLC. Progression-free survival (PFS) and hepatic PFS (hPFS) were estimated using the Kaplan-Meier method and compared using the log-rank test.
Results
475 patients were enrolled and 141 patients with lung cancers were analyzed, including 98 (69.5%) NSCLC and 43 (30.5%) SCLC. At data cut-off (Feb 28, 2023), the median follow-up was 7.27 months (95% CI, 6.97-7.63). The median PFS of NSCLC and SCLC were 5.80 months (95% CI, 5.00-7.20), 5.43 months (95% CI, 4.30-NE). The median hPFS of NSCLC and SCLC were 6.43 months (95% CI, 5.00-NE), 7.27 months (95% CI, 4.53-NE). The median OS of NSCLC and SCLC were 7.63 months (95% CI, 7.20-NE), NR (95% CI, 7.37-NE). There was not statistically significant between NSCLC and SCLC in PFS (p=0.63), hPFS (p=0.74) and OS (p=0.55). 27 (19.2%) patients had treatment-emergent adverse events (TEAEs) and 3 patients (2.1%) had ≥3 TEAEs. Most frequent TEAEs were hematological (19.2%) and gastrointestinal (5.0%) toxicities.
Conclusions
This study provides the largest real-world experience of anlotinib in solid tumors with liver metastases to date. For NSCLC and SCLC with liver metastases, anlotinib could be an effective and safe treatment option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.